Palivizumab
Palivizumab
Palivizumab (pronounced as pali-vizu-mab) is a monoclonal antibody specifically designed to provide passive immunity against Respiratory Syncytial Virus (RSV).
Etymology
The term "Palivizumab" is derived from the Latin roots 'pali-' meaning 'again', 'viz-' meaning 'force', and '-mab' is an abbreviation for 'monoclonal antibody'.
Usage
Palivizumab is used to prevent serious lung disease caused by a specific virus (RSV) in certain infants and children who are at high risk for severe disease from RSV. It works by preventing the growth of the virus, which helps to decrease the severity of the disease. Palivizumab does not help to cure RSV disease or prevent spread of RSV to others.
Related Terms
- Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Respiratory Syncytial Virus (RSV): A common respiratory virus that usually causes mild, cold-like symptoms.
- Passive Immunity: The short-term immunity that results from the introduction of antibodies from another person or animal.
- Antibody: A blood protein produced in response to and counteracting a specific antigen.
See Also
External links
- Medical encyclopedia article on Palivizumab
- Wikipedia's article - Palivizumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski